临床药师参与1例无乳链球菌致右股骨骨髓炎的病例分析
Clinical Pharmacist Participated in a Case Analysis of Right Femoral Osteomyelitis Caused by Streptococcus agalactiae
DOI: 10.12677/acm.2025.152391, PDF,   
作者: 普荣福*, 孙 丹, 李 淑, 刘会玲：昆明吉长庚骨科医院药剂科，云南 昆明；何 旭#：大理白族自治州人民医院药剂科，云南 大理
关键词: 无乳链球菌；骨髓炎；临床药师；抗菌药物；Streptococcus agalactiae； Osteomyelitis； Clinical Pharmacist； Antibacterial Drug
摘要: 目的：探讨无乳链球菌致骨髓炎的有效抗感染治疗方案。方法：临床药师参与患者的整个治疗过程，结合患者的症状、体征、实验室检查、感染部位，抗菌药物药动学特点、血药浓度，及时调整用药方案。结果：经过药物治疗后，患者体温，WBC、NEUT、NEUT%、CRP等感染指标均恢复正常，骨髓炎抗感染治疗有效。结论：临床药师已成为临床治疗中不可或缺的角色，能够为医师提供有价值的用药建议和参考。临床药师在临床合理用药中发挥重要作用。
Abstract: Objective: To explore an effective anti-infective treatment plan for osteomyelitis caused by Streptococcus agalactiae. Methods: Clinical pharmacist participated in the entire treatment process of the patient, combined with the patient’s symptoms, signs, laboratory examination, site of infection, pharmacokinetic characteristics and blood concentration of antimicrobial drugs, and timely adjustment of the drug regimen. Results: After drug treatment, the patient’s temperature, WBC, NEUT, NEUT%, CRP and other indicators of infection returned to normal, and the anti-infective treatment of osteomyelitis was effective. Conclusion: Clinical pharmacists have become an indispensable role in clinical treatment, able to provide physicians with valuable medication advice and reference. Clinical pharmacists play an important role in clinical rational drug use.
文章引用：普荣福, 孙丹, 李淑, 刘会玲, 何旭. 临床药师参与1例无乳链球菌致右股骨骨髓炎的病例分析[J]. 临床医学进展, 2025, 15(2): 656-660. https://doi.org/10.12677/acm.2025.152391

参考文献

[1] Martinaud, C., Gaillard, T., Graffin, B., et al. (2008) Vertebral Osteomyelitis Due to Streptococcus agalactiae ST-17. Annales de Biologie Clinique, 66, 87-89.
[2] Piccinelli, G., Biscaro, V., Gargiulo, F., Caruso, A. and De Francesco, M.A. (2015) Characterization and Antibiotic Susceptibility of Streptococcus agalactiae Isolates Causing Urinary Tract Infections. Infection, Genetics and Evolution, 34, 1-6. [Google Scholar] [CrossRef] [PubMed]
[3] 中华人民共和国国家卫生和计划生育委员会. 抗菌药物临床应用指导原则[M]. 北京: 人民卫生出版社, 2015: 68.
[4] 国家卫生计生委医政医管局, 国家卫生计生委合理用药专家委员会. 国家抗微生物治疗指南[M]. 第2版. 北京: 人民卫生出版社, 2018: 92-101.
[5] Graziani, A.L., Lawson, L.A., Gibson, G.A., Steinberg, M.A. and MacGregor, R.R. (1988) Vancomycin Concentrations in Infected and Noninfected Human Bone. Antimicrobial Agents and Chemotherapy, 32, 1320-1322. [Google Scholar] [CrossRef] [PubMed]
[6] Bolukaoto, J.Y., Monyama, C.M., Chukwu, M.O., Lekala, S.M., Nchabeleng, M., Maloba, M.R.B., et al. (2015) Antibiotic Resistance of Streptococcus agalactiae Isolated from Pregnant Women in Garankuwa, South Africa. BMC Research Notes, 8, Article No. 364. [Google Scholar] [CrossRef] [PubMed]
[7] Barros, R.R., Barros, C.C., Kegele, F.C.O., Francisca da S. N. Soares, M. and de Paula, G.R. (2024) Macrolide Resistance among Streptococcus agalactiae during COVID-19 Public Health Emergency in Brazil. Brazilian Journal of Microbiology, 55, 1445-1449. [Google Scholar] [CrossRef] [PubMed]
[8] Gonzalez Moreno, M., Trampuz, A. and Di Luca, M. (2017) Synergistic Antibiotic Activity against Planktonic and Biofilm-Embedded Streptococcus agalactiae, Streptococcus pyogenes and Streptococcus oralis. Journal of Antimicrobial Chemotherapy, 72, 3085-3092. [Google Scholar] [CrossRef] [PubMed]
[9] Livorsi, D.J., Daver, N.G., Atmar, R.L., Shelburne, S.A., White, A.C. and Musher, D.M. (2008) Outcomes of Treatment for Hematogenous Staphylococcus aureus Vertebral Osteomyelitis in the MRSA Era. Journal of Infection, 57, 128-131. [Google Scholar] [CrossRef] [PubMed]
[10] Amari, E.B., Vuagnat, A., Stern, R., et al. (2004) High versus Standard Dose Vancomycin for Osteomyelitis. Scandinavian Journal of Infectious Diseases, 36, 712-717.
[11] Moenster, R.P., Linneman, T.W., Finnegan, P.M. and McDonald, J.R. (2012) Daptomycin Compared to Vancomycin for the Treatment of Osteomyelitis: A Single-Center, Retrospective Cohort Study. Clinical Therapeutics, 34, 1521-1527. [Google Scholar] [CrossRef] [PubMed]
[12] Boselli, E., Breilh, D., Debon, R., Duflo, F., Bel, J.C., Saux, M.C., et al. (2002) Penetration of Piperacillin/Tazobactam (4 G/500 mg) into Synovial Tissue. Journal of Chemotherapy, 14, 54-58. [Google Scholar] [CrossRef] [PubMed]
[13] Perry, C.M. and Markham, A. (1999) Piperacillin/Tazobactam: An Updated Review of Its Use in the Treatment of Bacterial Infections. Drugs, 57, 805-843. [Google Scholar] [CrossRef] [PubMed]
[14] Moenster, R.P., Linneman, T.W., Finnegan, P.M., Hand, S., Thomas, Z. and McDonald, J.R. (2014) Acute Renal Failure Associated with Vancomycin and Β-Lactams for the Treatment of Osteomyelitis in Diabetics: Piperacillin-Tazobactam as Compared with Cefepime. Clinical Microbiology and Infection, 20, O384-O389. [Google Scholar] [CrossRef] [PubMed]
[15] 华春珍, 俞蕙, 庄捷秋, 等. 2011至2015年181例儿童无乳链球菌血流感染多中心研究[J]. 中华儿科杂志, 2016, 54(8): 577-581.
[16] Bauer, T.M., Pippert, H. and Zimmerli, W. (1997) Vertebral Osteomyelitis Caused by Group B Streptococci (Streptococcus agalactiae) Secondary to Urinary Tract Infection. European Journal of Clinical Microbiology & Infectious Diseases, 16, 244-246. [Google Scholar] [CrossRef] [PubMed]
[17] Solı́s-Garcia del Pozo, J., Martinez-Alfaro, E., Abad, L. and Solera, J. (2000) Vertebral Osteomyelitis Caused by Streptococcus agalactiae. Journal of Infection, 41, 84-90. [Google Scholar] [CrossRef] [PubMed]

为你推荐